Editorial: Molecular markers for pancreatic cancers: new technologies and applications in the clinical practice.
作者信息
Moyana Terence, Merz Valeria
机构信息
Diagnostic & Molecular Pathology, University of Ottawa and The Ottawa Hospital, Ottawa, ON, Canada.
Medical Oncology Unit, Santa Chiara Hospital, Trento, Italy.
出版信息
Front Oncol. 2025 Jul 8;15:1651566. doi: 10.3389/fonc.2025.1651566. eCollection 2025.
Abstract
摘要
相似文献
1
Editorial: Molecular markers for pancreatic cancers: new technologies and applications in the clinical practice.社论：胰腺癌的分子标志物：新技术及其在临床实践中的应用
Front Oncol. 2025 Jul 8;15:1651566. doi: 10.3389/fonc.2025.1651566. eCollection 2025.
2
Exosomes as prognostic biomarkers in pancreatic ductal adenocarcinoma-a systematic review and meta-analysis.外泌体作为胰腺导管腺癌的预后生物标志物：系统评价和荟萃分析。
Transl Res. 2022 Jun;244:126-136. doi: 10.1016/j.trsl.2022.01.001. Epub 2022 Jan 20.
3
Molecular Biomarkers for the Diagnosis and Prognostication of Pancreatic Ductal Adenocarcinoma.用于胰腺导管腺癌诊断和预后评估的分子生物标志物
J Pers Med. 2025 Jun 5;15(6):236. doi: 10.3390/jpm15060236.
4
Validation of two plasma multimetabolite signatures for patients at risk of or with suspected pancreatic ductal adenocarcinoma (METAPAC): a prospective, multicentre, investigator-masked, enrichment design, phase 4 diagnostic study.用于有胰腺导管腺癌风险或疑似胰腺导管腺癌患者的两种血浆多代谢物特征验证（METAPAC）：一项前瞻性、多中心、研究者设盲、富集设计的4期诊断性研究。
Lancet Gastroenterol Hepatol. 2025 Jul;10(7):634-647. doi: 10.1016/S2468-1253(25)00056-1. Epub 2025 May 16.
5
Immunohistochemical analysis of a panel of cancer stem cell markers and potential therapeutic markers in pancreatic ductal adenocarcinoma.免疫组织化学分析胰腺癌中一组癌症干细胞标志物和潜在治疗性标志物。
J Cancer Res Clin Oncol. 2023 Jun;149(6):2279-2292. doi: 10.1007/s00432-022-04315-4. Epub 2022 Sep 6.
6
Improving Outcomes in Pancreatic Adenocarcinoma: A Systematic Review of Immunotherapy in Multimodal Treatment.改善胰腺腺癌的治疗结果：多模式治疗中免疫疗法的系统评价
Medicina (Kaunas). 2025 Jun 11;61(6):1076. doi: 10.3390/medicina61061076.
7
Advanced Detection of Pancreatic Cancer Circulating Tumor Cells Using Biomarkers and Magnetic Particle Spectroscopy.利用生物标志物和磁性粒子光谱技术对胰腺癌循环肿瘤细胞进行高级检测。
Nanotheranostics. 2025 Jun 12;9(2):171-185. doi: 10.7150/ntno.110074. eCollection 2025.
8
Surfaceome profiling enables isolation of cancer-specific exosomal cargo in liquid biopsies from pancreatic cancer patients.表面组学分析可实现在胰腺癌患者的液体活检中分离出肿瘤特异性的细胞外囊泡 cargo。
Ann Oncol. 2018 Jan 1;29(1):223-229. doi: 10.1093/annonc/mdx542.
9
The ambiguous role of microRNA-205 and its clinical potential in pancreatic ductal adenocarcinoma.微小 RNA-205 作用不明确及其在胰腺导管腺癌中的临床潜力
J Cancer Res Clin Oncol. 2018 Dec;144(12):2419-2431. doi: 10.1007/s00432-018-2755-9. Epub 2018 Sep 22.
10
Tissue biomarkers for prognosis in pancreatic ductal adenocarcinoma: a systematic review and meta-analysis.用于胰腺导管腺癌预后的组织生物标志物：系统评价和荟萃分析。
Clin Cancer Res. 2011 May 15;17(10):3316-31. doi: 10.1158/1078-0432.CCR-10-3284. Epub 2011 Mar 28.
本文引用的文献
1
Vault Particles in Cancer Progression, Multidrug Resistance, and Drug Delivery: Current Insights and Future Applications.核小体颗粒在癌症进展、多药耐药性及药物递送中的研究现状与未来应用
Int J Mol Sci. 2025 Feb 12;26(4):1562. doi: 10.3390/ijms26041562.
2
Pancreatic cancer-derived extracellular vesicles enhance chemoresistance by delivering KRAS protein to cancer-associated fibroblasts.胰腺癌衍生的细胞外囊泡通过将KRAS蛋白传递给癌症相关成纤维细胞来增强化学抗性。
Mol Ther. 2025 Mar 5;33(3):1134-1153. doi: 10.1016/j.ymthe.2025.01.023. Epub 2025 Jan 14.
3
Prognostic Value of Residual Circulating Tumor DNA in Metastatic Pancreatic Ductal Adenocarcinoma.转移性胰腺导管腺癌中残留循环肿瘤DNA的预后价值
Ann Lab Med. 2025 Mar 1;45(2):199-208. doi: 10.3343/alm.2024.0345. Epub 2025 Jan 13.
4
Exosomes: from basic research to clinical diagnostic and therapeutic applications in cancer.外泌体：从基础研究到癌症的临床诊断与治疗应用
Cell Oncol (Dordr). 2025 Apr;48(2):269-293. doi: 10.1007/s13402-024-00990-2. Epub 2024 Sep 19.
5
FGFR2-fusions define a clinically actionable molecular subset of pancreatic cancer.FGFR2融合基因定义了胰腺癌中一个具有临床可操作性的分子亚群。
NPJ Precis Oncol. 2024 Sep 17;8(1):207. doi: 10.1038/s41698-024-00683-x.
6
Molecular insights to therapeutic in cancer: role of exosomes in tumor microenvironment, metastatic progression and drug resistance.癌症治疗的分子见解：外泌体在肿瘤微环境、转移进展和耐药性中的作用。
Drug Discov Today. 2024 Aug;29(8):104061. doi: 10.1016/j.drudis.2024.104061. Epub 2024 Jun 18.
7
Significance of TP53, CDKN2A, SMAD4 and KRAS in Pancreatic Cancer.TP53、CDKN2A、SMAD4和KRAS在胰腺癌中的意义
Curr Issues Mol Biol. 2024 Mar 23;46(4):2827-2844. doi: 10.3390/cimb46040177.
8
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.2022 年全球癌症统计数据：全球 185 个国家和地区 36 种癌症的发病率和死亡率全球估计数。
CA Cancer J Clin. 2024 May-Jun;74(3):229-263. doi: 10.3322/caac.21834. Epub 2024 Apr 4.
9
CA19-9 and CEA biosensors in pancreatic cancer.胰腺癌的 CA19-9 和 CEA 生物传感器。
Clin Chim Acta. 2024 Feb 1;554:117788. doi: 10.1016/j.cca.2024.117788. Epub 2024 Jan 20.
10
Pancreatic ductal adenocarcinoma staging: a narrative review of radiologic techniques and advances.胰腺导管腺癌分期：放射学技术与进展的叙述性综述
Int J Surg. 2024 Oct 1;110(10):6052-6063. doi: 10.1097/JS9.0000000000000899.
Zotero 插件